Quick Answer
Upstream Bio, Inc. reported Diluted EPS of $2.66 per share (loss) for fiscal year 2025.
Upstream Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.66 | +52.3% |
| 2024 | -$5.58 | +56.9% |
| 2023 | -$12.95 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.63 | +90.9% | +14.9% |
| June 30, 2025 | -$0.74 | +88.6% | -45.1% |
| March 31, 2025 | -$0.51 | +89.1% | +92.7% |
| September 30, 2024 | -$6.96 | -229.9% | -7.1% |
| June 30, 2024 | -$6.50 | — | -38.9% |
| March 31, 2024 | -$4.68 | — | -121.8% |
| September 30, 2023 | -$2.11 | — | — |
- Upstream Bio, Inc. showed an increase of +52.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Upstream Bio, Inc.’s diluted eps has grown by 79.5% (from $12.95 per share (loss) to $2.66 per share (loss)).
- The most recent figure is from Upstream Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: